This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy